Acorda On Track To File Oral MS Therapy By First Quarter 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Fampridine-SR did not affect heart rate in QT studies; final Phase III data available in second quarter.
You may also be interested in...
Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
Fampridine-SR Phase III Data Support Filing For Multiple Sclerosis, Acorda Says
Company targets first quarter 2009 for NDA submission; will position Fampridine-SR as an add-on to immunomodulators.
Novartis’ Oral MS Drug Strong In Three-year Phase II Data
Side effects rang alarms early on, but disappeared over time.